Clinical

This channel newsfeed includes clinical content on treating patients or the clinical implications in a variety of cardiac subspecialties and disease states. The channel includes news on cardiac surgery, interventional cardiology, heart failure, electrophysiology, hypertension, structural heart disease, use of pharmaceuticals, and COVID-19.   

RSS icon

C. R. Bard Receives FDA Premarket Approval of the LUTONIX® 035 Drug Coated Balloon as the First and Only DCB for the Treatment of Patients with Dysfunctional AV Fistulae

MURRAY HILL, N.J. — August 28, 2017 — C. R. Bard, Inc. (NYSE:BCR) today announced the LUTONIX® 035 Drug Coated Balloon PTA Catheter (DCB) has been granted premarket approval (PMA) by the U.S. Food and Drug Administration (FDA) for a new indication and is now available for sale in the United States. With this approval, the LUTONIX® 035 DCB Catheter becomes the first and only drug coated balloon that is FDA approved as safe and effective in end stage renal disease (ESRD) patients with stenotic lesions in dialysis arteriovenous (AV) fistulae.

Thumbnail

Diabetes drug gains FDA indication for CV benefit

The diabetes drug liraglutide (Victoza) secured an indication from the FDA to reduce the risk of major adverse cardiovascular (CV) events in adults with Type 2 diabetes and established cardiovascular disease, Novo Nordisk announced Aug. 25.

Prediction model underestimates CV risk in disadvantaged neighborhoods

A widely accepted model systematically underpredicts major atherosclerotic cardiovascular disease (ASCVD) risk in disadvantaged communities, according to a new study in Annals of Internal Medicine.

Thumbnail

Prostate cancer treatment associated with higher risk of heart failure

Men with early-stage prostate cancer who receive androgen deprivation therapy are at significantly higher risk for heart failure, according to a study published in the British Journal of Cancer.

Extended treatment with Brillinta reduces risk of cardiovascular death by 29% in patients with history of heart attack

August 24, 2017 — AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in CV death (p=0.0041) from treatment with Brilinta (ticagrelor) 60mg twice daily, versus placebo, in patients taking lowdose aspirin but still at high risk of an atherothrombotic event, a major cause of acute coronary syndrome and CV death.

Thumbnail

CDC: 2 of 3 heart attack patients spurn rehab

Despite proven survival benefits, roughly two-thirds of heart attack patients forego cardiac rehabilitation, according to a report from the Centers for Disease Control and Prevention (CDC).

CABG outperforms PCI in patients with type 1 diabetes

Coronary artery bypass grafting (CABG) demonstrates favorable results when compared to PCI in patients with type 1 diabetes (T1D), according to a new study in the Journal of the American College of Cardiology.

Ancient humans, genetic cousins faced higher risks of CVD

Visit any natural history museum and humankind’s ancestors are shown fighting the elements, large predators and one another to survive. But a recent study shows these folks had another thing to worry about: cardiovascular disease (CVD).

Displaying 5593 - 5600 of 10761

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.